Table 2. Treatment responses.

This table gives a summary of the treatment responses to continuous ketamine infusion for five to seven days. There was a significant reduction in the pain score and persistent relief in the responder group compared to the non-responder group.

^{AFP: Atypical facial pain.}

^† Student’s t-test; ^£ Chi-square: ^‡ Mann-Whitney; * Statistically significant.

	Responders (n = 7)	Non-responders (n = 5)	p-value
Changes in pain score post-ketamine treatment (average ± SD)	-6.4 ± 2.3	-2.4 ± 2.6	‡0.018*
Duration of ketamine infusion (days ± SD)	5.7 ± 0.5	5.8 ± 0.8	†0.57
Maximum infusion rate (mg/hr ± SD)	27.1 ± 3.9	34.0 ± 9.6	†0.12
Maximum infusion rate (mg/kg/hr ± SD)	0.37 ± 0.12	0.54 ± 0.9	†0.034*
Duration of post-ketamine pain relief (weeks ± SD)	10.3 ± 9.9	0 ± 0	†0.04*
Diagnosis (n)	TN: 6; AFP: 1	TN: 1; AFP: 4	£0.023*